I-Acute Lymphoblastic Leukemia (T-ALL)-08

UYesheng waseFujian uthe, "Ukube bengazi nge-CAR-T kwa-BIOOCUS Medical Group, ngabe ngize kusenesikhathi."

NgoSepthemba 2017, uYesheng waba nokuqubuka kobuso, okwasakazeka kancane kancane futhi kwahlangana kwaba amabala. Ngomhlaka-28 kuNhlolanja 2018, ukuhlolwa komnkantsha kwaqinisekisa "i-acute T-cell lymphoblastic leukemia" ngemva kwezifundo eziningi ze-chemotherapy, kanye nokuhlolwa okungekuhle okuhlala njalo. Yonke imithi yayekwa ngoJuni 2019.

NgoMeyi 2021, uYesheng wabonakala ekhuluphele endaweni yomlomo kanye ne-pharyngeal kanye nama-lymph node entamo akhulisiwe. Ukuhlolwa kabusha komnkantsha kwaqinisekisa ukubuyela emuva ngokuphelele kwe-leukemia. NgoMeyi 28, uYesheng wadluliselwa eMnyangweni Wesibili We-Hematology ukuze angeniswe. Ngemva kokuhlolwa okuphelele, ukuxilongwa kwabuyekezwa kwaba "i-leukemia ebukhali (T/myeloid biphenotypic)."

Umjikelezo owodwa we-chemotherapy awuzange ubangele ukuphulukiswa komongo wethambo. Ngomhlaka-27 kuJulayi, uYesheng wathola ukufakwa kweseli le-CD7 CAR-T, kwalandela ukwelashwa kwe-chemotherapy okuhlanganiswe nokwelashwa kweseli le-CD7 CAR-T nge-autologous. Ezinsukwini eziyishumi nanhlanu ngemuva kokufakwa, ukuhlolwa komnkantsha wethambo kwabonisa isifo esisele esibi, kanye nokusabela kwe-cytokine release syndrome (CRS) yebanga loku-1 futhi akukho ukusabela okubi kwesistimu yezinzwa ephakathi.